Solitary Fibrous Tumor Treatment Market Size, Share & Trends Report, 2022-2030
The global Solitary Fibrous Tumor Treatment market gathered revenue around USD 40.5 Million in 2021 and market is set to grow USD 65.3 Million by the end of 2030 and is estimated to expand at a modest CAGR of 4.5% during the prediction period 2022 to 2030.
Growth Factors:
Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that accounts for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple anatomic locations and can arise anywhere in the body. These tumors occur equally in both men and women, most frequently in the 6th and 7th decades of life.
Report Scope of the Solitary Fibrous Tumor Treatment Market
|
Report Coverage |
Details |
|
Market Size |
US$ 65.3 Million by 2030 |
|
Growth Rate |
CAGR of 4.5% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Treatment, End-user and Region, |
|
Companies Mentioned |
Pfizer, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Bayer AG, and Novartis AG. |
Improved Diagnostic Procedures to Drive Global Market
In the past few decades, sustained advances through research & technology have led to more reliable methods for differentiating this distinct soft tissue tumor. Advances, specifically in immunohistochemistry and molecular diagnostics, have identified CD34 as the most consistent marker in solitary fibrous tumor. More recently, the discovery of the NAB2-STAT6 fusion gene has led to more precise diagnosis of solitary fibrous tumor. Hence, improvement and new development of diagnostic procedures are anticipated to drive the global solitary fibrous tumor treatment market.
High Cost of Treatment to Hamper Global Market
Several studies have suggested that people with rare diseases face higher healthcare costs than those with common diseases. Solitary fibrous tumor is a very rare disease. Treatment involves surgery and therapies such as radiation therapy and chemotherapy. However, high cost of therapies and other immunotherapies is expected to deter patients from availing these treatments.
Surgery to be Remain Treatment Method
The global solitary fibrous tumor treatment market has been segmented based on treatment and end-user. In terms of treatment, the global solitary fibrous tumor market has been classified into surgery, radiation therapy, and adjuvant chemotherapy. The surgery segment is likely to account for major share of the global market by 2031, due to increase in demand for surgery, as surgical management has been the mainstay treatment for solitary fibrous tumor.
Hospitals to be Key End-user
In terms of end-user, the global solitary fibrous tumor treatment market has been divided into hospitals, ambulatory surgical centers, and others. The hospitals segment is projected to expand at a high CAGR during the forecast period due to rise in patient preference for all types of treatment facility under one roof.
North America to Dominate Global Market
The global solitary fibrous tumor treatment market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global solitary fibrous tumor treatment market in 2020, followed by Europe. North America accounted for major share of the global solitary fibrous tumor treatment market in 2020 due to high awareness and increase in demand for disease risk assessment services for cancer treatment.
The solitary fibrous tumor treatment market in Asia Pacific is projected to expand at a high CAGR from 2022 to 2030. Rise in number of patients, high healthcare expenditure, and geographic expansion by major players, especially in China and India, are anticipated to drive the solitary fibrous tumor treatment market in the region.
Some of the prominent players in the Solitary Fibrous Tumor Treatment Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global Solitary Fibrous Tumor Treatment Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Solitary Fibrous Tumor Treatment Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Solitary Fibrous Tumor Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, 2017–2030
5. Market Outlook
5.1. Pipeline Analysis
5.2. COVID-19 Impact Analysis
5.3. Patients Population Data, 2018-2020
6. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
6.2.1. Surgery
6.2.2. Radiation Therapy
6.2.3. Adjuvant Chemotherapy
6.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Treatment
7. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Global Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2030
7.2.1. Ambulatory Surgical Centers
7.2.2. Hospitals
7.2.3. Others
7.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by End-user
8. Global Solitary Fibrous Tumor Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Solitary Fibrous Tumor Treatment Market Attractiveness Analysis, by Region
9. North America Solitary Fibrous Tumor Treatment Market Analysis and Forecast
9.1. Introduction
9.2. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
9.2.1. Surgery
9.2.2. Radiation Therapy
9.2.3. Adjuvant Chemotherapy
9.3. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2030
9.3.1. Ambulatory Surgical Centers
9.3.2. Hospitals
9.3.3. Others
9.4. North America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2030
9.4.1. U.S.
9.4.2. Canada
9.5. North America Solitary Fibrous Tumor Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Solitary Fibrous Tumor Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Europe Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
10.2.1. Surgery
10.2.2. Radiation Therapy
10.2.3. Adjuvant Chemotherapy
10.3. Europe Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by End-user, 2017–2030
10.3.1. Ambulatory Surgical Centers
10.3.2. Hospitals
10.3.3. Others
10.4. Europe Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Solitary Fibrous Tumor Treatment Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Solitary Fibrous Tumor Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Asia Pacific Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
11.2.1. Surgery
11.2.2. Radiation Therapy
11.2.3. Adjuvant Chemotherapy
11.3. Asia Pacific Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2030
11.3.1. Ambulatory Surgical Centers
11.3.2. Hospitals
11.3.3. Others
11.4. Asia Pacific Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Solitary Fibrous Tumor Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Solitary Fibrous Tumor Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
12.2.1. Surgery
12.2.2. Radiation Therapy
12.2.3. Adjuvant Chemotherapy
12.3. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2030
12.3.1. Ambulatory Surgical Centers
12.3.2. Hospitals
12.3.3. Others
12.4. Latin America Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Solitary Fibrous Tumor Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Solitary Fibrous Tumor Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Middle East & Africa Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
13.2.1. Surgery
13.2.2. Radiation Therapy
13.2.3. Adjuvant Chemotherapy
13.3. Middle East & Africa Solitary Fibrous Tumor Market Value (US$ Mn) Forecast, by End-user, 2017–2030
13.3.1. Ambulatory Surgical Centers
13.3.2. Hospitals
13.3.3. Others
13.4. Middle East & Africa Solitary Fibrous Tumor Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Solitary Fibrous Tumor Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country/Sub-region
13.5.4. Competition Landscape
13.6. Competition Landscape
13.7. Company Profiles
13.7.1. Pfizer, Inc.
13.7.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.7.1.2. Growth Strategies
13.7.1.3. SWOT Analysis
13.7.2. F. Hoffmann-La Roche Ltd.
13.7.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.7.2.2. Growth Strategies
13.7.2.3. SWOT Analysis
13.7.3. Eli Lilly and Company
13.7.3.1. Company Overview (HQ, Business Segments)
13.7.3.2. Growth Strategies
13.7.3.3. SWOT Analysis
13.7.4. Bayer AG
13.7.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.7.4.2. Growth Strategies
13.7.4.3. SWOT Analysis
13.7.5. Novartis AG
13.7.5.1. Company Overview (HQ, Business Segments)
13.7.5.2. Growth Strategies
13.7.5.3. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers